Your browser is no longer supported. Please, upgrade your browser.
Settings
CANF [AMEX]
Can-Fite BioPharma Ltd.
Index- P/E- EPS (ttm)-1.47 Insider Own1.19% Shs Outstand15.41M Perf Week-2.62%
Market Cap28.67M Forward P/E- EPS next Y-0.68 Insider Trans0.00% Shs Float14.76M Perf Month1.64%
Income- PEG- EPS next Q-0.26 Inst Own6.52% Short Float1.96% Perf Quarter2.25%
Sales0.81M P/S35.61 EPS this Y62.70% Inst Trans- Short Ratio0.63 Perf Half Y-13.49%
Book/sh0.63 P/B2.95 EPS next Y44.70% ROA- Target Price- Perf Year-31.87%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.08 - 2.95 Perf YTD4.49%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.95% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low72.22% ATR0.10
Employees8 Current Ratio- Sales Q/Q-81.70% Oper. Margin- RSI (14)49.12 Volatility5.71% 4.41%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.06 Prev Close1.90
ShortableYes LT Debt/Eq- EarningsNov 30 BMO Payout- Avg Volume458.76K Price1.86
Recom2.00 SMA200.13% SMA500.42% SMA200-3.07% Volume485,804 Change-2.11%
Aug-11-17Initiated Maxim Group Buy $7
Oct-19-16Resumed ROTH Capital Buy
Aug-29-16Resumed Rodman & Renshaw Buy $6
Nov-30-15Reiterated H.C. Wainwright Buy $4 → $6
Mar-31-15Reiterated H.C. Wainwright Buy $7 → $3
Mar-30-15Downgrade ROTH Capital Buy → Neutral $20 → $2.40
Dec-29-14Reiterated ROTH Capital Buy $28 → $20
Nov-18-14Initiated H.C. Wainwright Buy $7
Jan-19-21 01:26PM  
Jan-08-21 07:00AM  
Jan-04-21 07:00AM  
Dec-22-20 06:00AM  
Dec-15-20 07:00AM  
Dec-14-20 07:00AM  
Dec-03-20 07:00AM  
Nov-30-20 07:00AM  
Nov-24-20 07:00AM  
Nov-23-20 07:00AM  
Nov-16-20 07:00AM  
Nov-09-20 07:00AM  
Oct-15-20 08:03AM  
Oct-13-20 07:00AM  
Oct-06-20 07:30AM  
Sep-30-20 07:00AM  
Sep-22-20 07:00AM  
Sep-08-20 07:00AM  
Aug-31-20 05:00PM  
07:00AM  
Aug-27-20 07:00AM  
Aug-26-20 07:00AM  
Aug-25-20 08:09AM  
Aug-20-20 07:00AM  
Aug-05-20 09:00AM  
Jul-27-20 07:00AM  
Jul-20-20 07:00AM  
Jul-15-20 07:00AM  
Jul-06-20 08:00AM  
Jun-30-20 07:00AM  
Jun-10-20 08:00AM  
Jun-09-20 07:00AM  
Jun-08-20 07:25AM  
Jun-04-20 07:14AM  
Jun-03-20 07:00AM  
Jun-01-20 07:00AM  
06:30AM  
May-28-20 07:00AM  
May-21-20 07:00AM  
May-18-20 07:00AM  
May-15-20 07:00AM  
Apr-28-20 11:04AM  
Apr-27-20 09:48AM  
Apr-14-20 07:00AM  
Apr-13-20 09:54AM  
06:30AM  
Apr-07-20 09:00AM  
Mar-30-20 07:00AM  
Mar-27-20 07:00AM  
Mar-23-20 07:45AM  
Mar-18-20 07:00AM  
Mar-16-20 07:00AM  
Mar-13-20 10:53AM  
08:13AM  
07:54AM  
07:00AM  
Mar-11-20 11:06AM  
07:30AM  
Mar-06-20 10:45AM  
Mar-05-20 08:05AM  
07:00AM  
Mar-03-20 07:00AM  
Feb-27-20 06:00AM  
Feb-24-20 07:00AM  
Feb-18-20 07:10AM  
Feb-13-20 07:00AM  
Feb-10-20 02:48PM  
Feb-03-20 07:30AM  
Jan-16-20 07:00AM  
Jan-09-20 09:10AM  
Jan-07-20 08:20AM  
Jan-06-20 10:06AM  
07:00AM  
Jan-03-20 07:00AM  
Dec-30-19 09:17AM  
Dec-27-19 10:02AM  
Dec-26-19 07:00AM  
Dec-09-19 08:15AM  
Dec-05-19 07:00AM  
Nov-29-19 08:20AM  
07:00AM  
Nov-21-19 07:00AM  
Nov-19-19 07:00AM  
Nov-11-19 09:51AM  
07:00AM  
Nov-04-19 07:00AM  
Oct-31-19 07:00AM  
Oct-17-19 08:00AM  
Oct-16-19 07:00AM  
Oct-15-19 06:30AM  
Oct-10-19 07:00AM  
Sep-23-19 07:00AM  
Sep-11-19 01:16PM  
Sep-10-19 08:10AM  
06:03AM  
05:38AM  
Aug-29-19 07:00AM  
Aug-06-19 07:00AM  
Aug-01-19 09:38AM  
Jul-10-19 09:56AM  
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.